MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB)

• Tranche-based financing to support clinical development for the Company’s late-stage assets in hemato-oncology including Xervyteg® currently under review for potential approval by the EMA and MaaT033 currently in Phase 2b clinical evaluation

• Funding is part of the European Investment Bank (EIB)’s strategy to support biotech companies with cutting-edge expertise in therapeutic areas such as hemato-oncology

• Structured Debt financing from the EIB is another stepping stone in MaaT Pharma’s multi-sourcing financing strategy

Lyon, France, July 28, 2025 – 7:30am CET – MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announced that it has secured a €37.5 million, 4-tranche financing from the European Investment Bank (EIB). The financing will support the advancement of its late-stage hemato-oncology clinical programs including the lead-asset Xervyteg®, recently partnered with Clinigen in Europe, and currently under regulatory review by the European Medicines Agency (EMA) for the treatment of acute Graft-versus-Host Disease (aGvHD) and the second drug candidate, MaaT033, currently being evaluated in a Phase 2b randomized controlled trial in improving survival for patients receiving allogeneic stem cell transplants.

Read the press release